vivo blocking antibody against mouse pd 1 (Bio X Cell)
Bio X Cell is a verified supplier 
Bio X Cell manufactures this product 
94
Structured Review
Bio X Cell
vivo blocking antibody against mouse pd 1
Vivo Blocking Antibody Against Mouse Pd 1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 41 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd-1+blocking+antibody/InVivoPlus+anti-mouse+PD-1/pmc12886529-85-11-19
Average 94 stars, based on 41 article reviews
Vivo Blocking Antibody Against Mouse Pd 1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 41 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd-1+blocking+antibody/InVivoPlus+anti-mouse+PD-1/pmc12886529-85-11-19
Average 94 stars, based on 41 article reviews
vivo blocking antibody against mouse pd 1 - by Bioz Stars,
2026-10
94/100 stars
Images
1) Product Images from "Chloride channel accessory 4 suppresses stem cell-like properties of colorectal cancer and enhances anti-PD-1 immunotherapy"
Article Title: Chloride channel accessory 4 suppresses stem cell-like properties of colorectal cancer and enhances anti-PD-1 immunotherapy
Journal: Genes & Diseases
doi: 10.1016/j.gendis.2025.101859
Figure Legend Snippet: CLCA4 overexpression enhanced the therapeutic effect of anti-PD-1. (A) In vivo tumorigenicity assay in nude mice was performed to detect the therapeutic effect of CLCA4 overexpression combined with anti-PD-1 antibody. (B) Tumor growth curve was monitored from nude mice with different treatment groups. (C) Weights of tumors from nude mice with different treatments were detected. One-way ANOVA with Tukey's multiple comparisons test (mean ± standard deviation). (D) Analysis of the survival times of mice in each group ( n = 8 per group), and the experiment was terminated 60 days after tumor inoculation. Unpaired two-tailed t -test (mean ± standard deviation). (E) Immunofluorescence or immunohistochemistry staining was performed to detect the infiltration levels of CD8 + T cells, GZMB, Perforin + cells, Ki67 + , Bmi-1 + , and Oct4 + cells in tumors from different treatment groups. One-way ANOVA with Tukey's multiple comparisons test (mean ± standard deviation). (F) Hematoxylin-eosin staining of liver metastases in each group. (G) Quantitative analysis of the liver weight in each group. One-way ANOVA with Tukey's multiple comparisons test (mean ± standard deviation). (H) Quantitative analysis of the liver metastasis area/total liver area in each group. One-way ANOVA with Tukey's multiple comparisons test (mean ± standard deviation).
Techniques Used: Over Expression, In Vivo, Tumorigenicity Assay, Standard Deviation, Two Tailed Test, Immunofluorescence, Immunohistochemistry, Staining
Related Articles
Injection:Article Title: Anti-PD-1 antibodies for treatment of lung cancer Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: Methods of treating skin cancer by administering a PD-1 inhibitor Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Article Title: PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma Article Snippet: Where indicated, mice were intraperitoneally (i.p.) injected with anti-asialo GM1 or isotype (Wako) every third day (day 0, 3, 6, 9, 12), and/or PD-1 blocking antibody or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Blocking Assay:Article Title: Anti-PD-1 antibodies for treatment of lung cancer Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: Methods of treating skin cancer by administering a PD-1 inhibitor Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Article Title: PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma Article Snippet: Where indicated, mice were intraperitoneally (i.p.) injected with anti-asialo GM1 or isotype (Wako) every third day (day 0, 3, 6, 9, 12), and/or PD-1 blocking antibody or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Expressing:Article Title: Anti-PD-1 antibodies for treatment of lung cancer Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: Methods of treating skin cancer by administering a PD-1 inhibitor Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Article Title: PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma Article Snippet: Where indicated, mice were intraperitoneally (i.p.) injected with anti-asialo GM1 or isotype (Wako) every third day (day 0, 3, 6, 9, 12), and/or PD-1 blocking antibody or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Flow Cytometry:Article Title: Anti-PD-1 antibodies for treatment of lung cancer Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: Methods of treating skin cancer by administering a PD-1 inhibitor Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Article Title: PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma Article Snippet: Where indicated, mice were intraperitoneally (i.p.) injected with anti-asialo GM1 or isotype (Wako) every third day (day 0, 3, 6, 9, 12), and/or PD-1 blocking antibody or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Isolation:Article Title: Anti-PD-1 antibodies for treatment of lung cancer Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: Methods of treating skin cancer by administering a PD-1 inhibitor Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Article Title: PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma Article Snippet: Where indicated, mice were intraperitoneally (i.p.) injected with anti-asialo GM1 or isotype (Wako) every third day (day 0, 3, 6, 9, 12), and/or PD-1 blocking antibody or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Cell Culture:Article Title: Anti-PD-1 antibodies for treatment of lung cancer Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: Methods of treating skin cancer by administering a PD-1 inhibitor Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Article Title: PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma Article Snippet: Where indicated, mice were intraperitoneally (i.p.) injected with anti-asialo GM1 or isotype (Wako) every third day (day 0, 3, 6, 9, 12), and/or PD-1 blocking antibody or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Staining:Article Title: Anti-PD-1 antibodies for treatment of lung cancer Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: Methods of treating skin cancer by administering a PD-1 inhibitor Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Article Title: PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma Article Snippet: Where indicated, mice were intraperitoneally (i.p.) injected with anti-asialo GM1 or isotype (Wako) every third day (day 0, 3, 6, 9, 12), and/or PD-1 blocking antibody or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of In Vivo:Article Title: Anti-PD-1 antibodies for treatment of lung cancer Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: Methods of treating skin cancer by administering a PD-1 inhibitor Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Article Title: PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma Article Snippet: Where indicated, mice were intraperitoneally (i.p.) injected with anti-asialo GM1 or isotype (Wako) every third day (day 0, 3, 6, 9, 12), and/or PD-1 blocking antibody or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Luminex:Article Title: Anti-PD-1 antibodies for treatment of lung cancer Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: Methods of treating skin cancer by administering a PD-1 inhibitor Article Snippet: The mice were randomly assigned to receive either isotype control (2A3, BioXcell) or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of Article Title: PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma Article Snippet: Where indicated, mice were intraperitoneally (i.p.) injected with anti-asialo GM1 or isotype (Wako) every third day (day 0, 3, 6, 9, 12), and/or PD-1 blocking antibody or Article Title: HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade Article Snippet: Assessment of tumor growth and survival was performed after intraperitoneal administration of 15mg/kg of LBH589 three times a week (Monday, Wednesday, Friday) alone or in combination with 3mg/kg of |
